<SEC-DOCUMENT>0001209191-21-037800.txt : 20210603
<SEC-HEADER>0001209191-21-037800.hdr.sgml : 20210603
<ACCEPTANCE-DATETIME>20210603173307
ACCESSION NUMBER:		0001209191-21-037800
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210601
FILED AS OF DATE:		20210603
DATE AS OF CHANGE:		20210603

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Knowles Julius
		CENTRAL INDEX KEY:			0001808365

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39264
		FILM NUMBER:		21993763

	MAIL ADDRESS:	
		STREET 1:		C/O KEROS THERAPEUTICS, INC.
		STREET 2:		99 HAYDEN AVENUE, SUITE 120, BUILDING E
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Keros Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001664710
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		99 HAYDEN AVENUE, SUITE 120 (BLD E)
		STREET 2:		LEDGEMONT TECHNOLOGY CENTER
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		617-513-8774

	MAIL ADDRESS:	
		STREET 1:		99 HAYDEN AVENUE, SUITE 120 (BLD E)
		STREET 2:		LEDGEMONT TECHNOLOGY CENTER
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-06-01</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001664710</issuerCik>
        <issuerName>Keros Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>KROS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001808365</rptOwnerCik>
            <rptOwnerName>Knowles Julius</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O KEROS THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>99 HAYDEN AVENUE, SUITE 120, BUILDING E</rptOwnerStreet2>
            <rptOwnerCity>LEXINGTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02421</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>51.48</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2021-06-01</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>8293</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2031-05-31</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>8293</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>8293</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be
fully vested on the date of Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through
each such date.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Keith Regnante, Attorney-in-Fact</signatureName>
        <signatureDate>2021-06-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
